View Post

Oncology Pharmacists Should Be Aware of the Benefits, Risks of Cannabis

In Clinical Studies News by Barbara Jacoby

By: Aislinn Antrim, Assistant Editor From: ALTHOUGH CANNABIS IS still considered a Schedule I agent by the Drug Enforcement Administration, many patients with cancer turn to cannabis products for relief from some of the adverse events (AEs) associated with treatment. For this reason, and because of changing attitudes around marijuana use, oncology pharmacists should educate themselves on the uses …